What an incredible two days it has been for Mustang Bio (NASDAQ:MBIO). On Wednesday, April 17, the company announced that it entered a licensing agreement with St. Jude Children’s Research Hospital to develop the lentiviral gene therapy to treat “bubble boy” disease. Today, MBIO stock is soaring, currently up more than 100%.
Here’s what we know.
MBIO Stock Soaring Because of New Mustang Bio Licensing AgreementYesterday, Mustang Bio posted a press release stating it has entered into a licensing agreement with St. Jude Children’s Research Hospital. Together, the lentiviral gene therapy will be ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.